NASH has the potential to be a large and lucrative therapy market owing to the disease’s prevalence and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…
Systemic sclerosis (SSc) is a rare, progressive, debilitating autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that manifests as Raynaud’s disease, skin…
NASH is an increasingly prevalent disease characterized by excess lipid (steatosis) in the liver, resulting in inflammation and eventually liver fibrosis. Ensuing complications can include liver…
Cystic fibrosis (CF) is a genetic disease caused by any one of the more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR mutations lead…
Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and varying degrees of vasculopathy that manifest as Raynaud…
Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and varying degrees of vasculopathy that manifest as Raynaud…
DRG Epidemiology's coverage of idiopathic pulmonary fibrosis comprises epidemiological estimates of key patient populations globally, including the major mature pharmaceutical markets (the…
DRG Epidemiology's coverage of idiopathic pulmonary fibrosis comprises epidemiological estimates of key patient populations globally, including the major mature pharmaceutical markets (the…
DRG Epidemiology's coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations globally, including the major mature pharmaceutical markets (…
DRG Epidemiology's coverage of idiopathic pulmonary fibrosis comprises epidemiological estimates of key patient populations globally, including the major mature pharmaceutical markets (the…
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…
Clarivate Epidemiology's coverage of NASH comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report prevalence of NASH for each country, as well as…
Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases and is characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first…
The systemic sclerosis (SSc) pipeline is replete with therapies targeting pathways underlying autoimmunity, inflammation, and fibrosis, particularly in the early phases of development. Currently,…
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…